Navigation Links
Unique New Initiative by World-Recognized Specialists in Heart Disease and Diabetes to Reduce Residual Vascular Risk Launched Today
Date:11/9/2008

NEW ORLEANS and LOS ANGELES, November 10 /PRNewswire/ --

- Current Treatment Fails to Abolish Majority of Vascular Risk

- Residual Risk Reduction Initiative (R3i) Calls for Action to Reduce the Lipid-Related Residual Vascular Risk Unaddressed by Current Standards of Care in Millions of Patients With Heart Disease and Diabetes

Internationally recognized specialists from North America, Europe, Asia and Japan have come together today to launch the Residual Risk Reduction initiative (R3i) - a unique global program to evaluate and reduce the excess risk of myocardial infarction, stroke, kidney disease, loss of vision and non-traumatic limb amputation which exists in many patients with heart disease and diabetes despite optimal, currently available care.

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and microvascular complications in patients with atherogenic dyslipidemia, characterized by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care. This lipid abnormality is typical in patients with type 2 diabetes or metabolic syndrome and common in patients with established cardiovascular disease.

The President of the R3i, Professor Jean-Charles Fruchart of the University of Lille, France said: "We now have unequivocal evidence from numerous studies showing that greater reductions in low-density lipoprotein cholesterol, blood pressure and blood sugar alone will have little, if any, additional impact on residual vascular risk. Therefore, we urgently need new strategies to address other modifiable risk factors such as atherogenic dyslipidemia, a strong contributor to residual vascular risk in millions of patients with diabetes and cardiovascular disease."

The R3i will address this major public health problem. In its manifesto published today in Diabetes & Vascular
'/>"/>

SOURCE Residual Risk Reduction Initiative (R3i)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nanoscience Instruments, Inc. Announces Distribution of Nascatec's Complete Line of Unique AFM Probes and Sensors
2. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
3. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
4. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
5. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
6. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
7. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
8. Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism
9. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
10. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
11. Unique infrared technique finds applications in nanoscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market ... Administration (FDA) for the use of Medtronic,s SynchroMed ... a newly developed catheter) for use with United ... to patients with pulmonary arterial hypertension.   ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... 2014 Earlier this year in a ... director of the Adult Stem Cell Technology Center, LLC ... and under appreciated unique property of adult tissue stem ... Cells: Misunderstood in the Past, Important for the Future,” ... He gave the address at the 4th World ...
(Date:12/24/2014)... According to Ross Selinger, President of ... Global, the national office market continues to be strong, driven ... evidenced by the third quarter’s surprising 3.9% GDP, unemployment decreasing ... costs have held inflation down and the Fed is keeping ... market remaining soft. , This solid economic news is having ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... First 9 Months Compared with Fiscal 2007,Net Income To ... MOUNTAIN VIEW, Calif., Jan. 24 Pharsight,Corporation (Nasdaq: ... strategic,services designed to optimize clinical drug development, today announced,financial ... December 31,2007. Revenue for the third quarter was $7.4 ...
... Call and Webcast Scheduled for Tuesday, February 5, ... NBIX ) announced today that the Company will report ... Nasdaq market closes,on Tuesday, February 5, 2008. Neurocrine will ... its financial results and provide a Company,update Tuesday afternoon, ...
... /PRNewswire-FirstCall/,-- Cephalon, Inc., (Nasdaq: CEPH ) announced ... Human Use (CHMP) of the European,Medicines Agency has ... buccal tablet pain medication. In March 2007, Cephalon,submitted ... treatment of,breakthrough pain in adult cancer patients who ...
Cached Biology Technology:Pharsight Achieves $7.4 Million in Quarterly Revenue 2Pharsight Achieves $7.4 Million in Quarterly Revenue 3Pharsight Achieves $7.4 Million in Quarterly Revenue 4Pharsight Achieves $7.4 Million in Quarterly Revenue 5Pharsight Achieves $7.4 Million in Quarterly Revenue 6Pharsight Achieves $7.4 Million in Quarterly Revenue 7Pharsight Achieves $7.4 Million in Quarterly Revenue 8Pharsight Achieves $7.4 Million in Quarterly Revenue 9Pharsight Achieves $7.4 Million in Quarterly Revenue 10Pharsight Achieves $7.4 Million in Quarterly Revenue 11Pharsight Achieves $7.4 Million in Quarterly Revenue 12Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Clinical Practices (GCP) audit to confirm its adherence ... regulations. This accomplishment enables HITLAB to conduct regulated ... the highest principles for patient safety and research ... global healthcare access, quality, and delivery with innovative ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... A breakthrough in human stem cell research, producing embryonic-like ... the development of treatments for life-threatening illnesses, injuries and ... experts from the University of Texas Medical Branch and ... researchers and physicians with an ethical and reliable source ...
... rise, and the loss of sand dune plant habitats" ... to better understand the impacts of development and coastal ... the ever-shrinking strip of habitat between land and the ... simulated varying levels of sea-level rise to understand the ...
... the body, a virus such as HIV invades body cells ... Once inside the cell, the invading microbe's genetic material takes ... more copies of the virus, which then spill out to ... that once a virus begins fusing with a cell's membrane, ...
Cached Biology News:Insight into the processes of 'positive' and 'negative' learners 2Squeezing out dune plants 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 2Several minute intermediate stage in virus-cell fusion discovered; opportunity for drug development 3
B-FABP (FL-132)...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
... Lambda Protein Phosphatase ( ... protein phosphatase with activity ... and tyrosine residues. It ... product of the ORF221 ...
Strip Removal Tool 25/Box...
Biology Products: